Sociodemographic and clinical characteristics of phase-4 participating patients with HL
| . | HL N = 381 . |
|---|---|
| . | n (%) . |
| Country (language) | |
| Austria (German) | 28 (7) |
| China (Chinese) | 35 (9) |
| Croatia (Croatian) | 20 (5) |
| France (French) | 16 (4) |
| Germany (German) | 5 (1) |
| Greece (Greek) | 3 (1) |
| Italy (Italian) | 17 (4) |
| Jordan (Jordanian Arabic) | 68 (18) |
| Lithuania (Lithuanian) | 14 (4) |
| Netherlands (Dutch) | 70 (18) |
| Portugal (Portuguese) | 56 (15) |
| United Kingdom (English) | 49 (13) |
| Sociodemographic information | |
| Age (y): mean (SD), median, range | 41.3 (16.8), 37, 18-89 |
| Sex | |
| Male | 213 (56) |
| Female | 167 (44) |
| Missing | 1 (<1) |
| Living arrangement | |
| Living with partner/family | 320 (84) |
| Living with others | 8 (2) |
| Living alone | 42 (11) |
| Missing | 10 (3) |
| Education | |
| No or primary school | 23 (6) |
| Secondary education | 111 (29) |
| Preuniversity training, university | 230 (60) |
| Missing | 16 (4) |
| Employment | |
| Employed | 200 (52) |
| Unemployed | 67 (18) |
| Retired, homemaker | 90 (24) |
| Training/education | 17 (4) |
| Missing | 7 (2) |
| Disease-related information | |
| Treatment received | |
| Systemic therapy (chemotherapy and/or immunotherapy) | 366 (96) |
| Radiotherapy | 133 (35) |
| Treatment line | |
| First | 319 (84) |
| Subsequent | 29 (8) |
| Missing | 33 (9) |
| On active treatment at time of baseline questionnaire | |
| Yes | 165 (43) |
| No | 200 (52) |
| Missing | 16 (4) |
| Time since start last active treatment | |
| On treatment to <3 mo | 168 (44) |
| 3 mo to 1 y | 65 (17) |
| >1 y | 128 (34) |
| Missing | 20 (5) |
| Time since diagnosis, y: mean (SD), median | 2.9 (4.8), 1 |
| <1 | 171 (45) |
| 1-3 | 83 (22) |
| 3-5 | 31 (8) |
| >5 | 61 (16) |
| Missing | 35 (10) |
| Stage of disease (Ann Arbor) | |
| I | 32 (8) |
| II | 150 (39) |
| III | 65 (17) |
| IV | 112 (29) |
| Missing | 22 (6) |
| Comorbidity | |
| No | 236 (62) |
| 1 | 72 (19) |
| ≥2 | 64 (17) |
| Missing | 9 (2) |
| Most common comorbidities | |
| Diabetes | 23 (6) |
| Thyroid disease | 18 (5) |
| Lung condition | 12 (3) |
| High blood pressure | 28 (7) |
| Heart condition | 27 (7) |
| ECOG | |
| 0 | 230 (60) |
| 1 | 94 (25) |
| 2 | 15 (4) |
| 3 | 3 (<1) |
| Missing | 39 (10) |
| . | HL N = 381 . |
|---|---|
| . | n (%) . |
| Country (language) | |
| Austria (German) | 28 (7) |
| China (Chinese) | 35 (9) |
| Croatia (Croatian) | 20 (5) |
| France (French) | 16 (4) |
| Germany (German) | 5 (1) |
| Greece (Greek) | 3 (1) |
| Italy (Italian) | 17 (4) |
| Jordan (Jordanian Arabic) | 68 (18) |
| Lithuania (Lithuanian) | 14 (4) |
| Netherlands (Dutch) | 70 (18) |
| Portugal (Portuguese) | 56 (15) |
| United Kingdom (English) | 49 (13) |
| Sociodemographic information | |
| Age (y): mean (SD), median, range | 41.3 (16.8), 37, 18-89 |
| Sex | |
| Male | 213 (56) |
| Female | 167 (44) |
| Missing | 1 (<1) |
| Living arrangement | |
| Living with partner/family | 320 (84) |
| Living with others | 8 (2) |
| Living alone | 42 (11) |
| Missing | 10 (3) |
| Education | |
| No or primary school | 23 (6) |
| Secondary education | 111 (29) |
| Preuniversity training, university | 230 (60) |
| Missing | 16 (4) |
| Employment | |
| Employed | 200 (52) |
| Unemployed | 67 (18) |
| Retired, homemaker | 90 (24) |
| Training/education | 17 (4) |
| Missing | 7 (2) |
| Disease-related information | |
| Treatment received | |
| Systemic therapy (chemotherapy and/or immunotherapy) | 366 (96) |
| Radiotherapy | 133 (35) |
| Treatment line | |
| First | 319 (84) |
| Subsequent | 29 (8) |
| Missing | 33 (9) |
| On active treatment at time of baseline questionnaire | |
| Yes | 165 (43) |
| No | 200 (52) |
| Missing | 16 (4) |
| Time since start last active treatment | |
| On treatment to <3 mo | 168 (44) |
| 3 mo to 1 y | 65 (17) |
| >1 y | 128 (34) |
| Missing | 20 (5) |
| Time since diagnosis, y: mean (SD), median | 2.9 (4.8), 1 |
| <1 | 171 (45) |
| 1-3 | 83 (22) |
| 3-5 | 31 (8) |
| >5 | 61 (16) |
| Missing | 35 (10) |
| Stage of disease (Ann Arbor) | |
| I | 32 (8) |
| II | 150 (39) |
| III | 65 (17) |
| IV | 112 (29) |
| Missing | 22 (6) |
| Comorbidity | |
| No | 236 (62) |
| 1 | 72 (19) |
| ≥2 | 64 (17) |
| Missing | 9 (2) |
| Most common comorbidities | |
| Diabetes | 23 (6) |
| Thyroid disease | 18 (5) |
| Lung condition | 12 (3) |
| High blood pressure | 28 (7) |
| Heart condition | 27 (7) |
| ECOG | |
| 0 | 230 (60) |
| 1 | 94 (25) |
| 2 | 15 (4) |
| 3 | 3 (<1) |
| Missing | 39 (10) |